The U.S. Food and Drug Administration (FDA) has granted approval for application ANDA087463. The approved product is marketed under the brand name Oxycet, a prescription oral tablet that combines oxycodone hydrochloride (5 mg) with acetaminophen (325 mg).
The product is classified as a human prescription drug and is manufactured by SpecGx LLC. It is listed under the generic name Oxycodone Hydrochloride and Acetaminophen and is available in multiple NDC package codes (e.g., 0406-0512-01, 0406-0522-05, etc.).
Submission history shows a series of manufacturing (CMC) and labeling supplements dating back to 1988, with the most recent labeling supplement (submission number 56) approved on March 4, 2024. All submissions to date have received an "AP" (Approved) status.
The tablet is intended for oral administration and is designated as a prescription‑only medication.
규제 업데이트2026년 9월 28일•1분 읽기
FDA Approves ANDA087463 for Oxycet (Oxycodone/Acetaminophen) Tablet
The FDA has approved ANDA087463 for the oral tablet Oxycet, containing 5 mg oxycodone hydrochloride and 325 mg acetaminophen, manufactured by SpecGx LLC.
PharmaCountry 팀이 정리했습니다 · 출처: FDA.gov
평점
(0)
(0)
(0)
(0)
(0)
평가 남기기